Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan

Serge A.L. Zander(The Netherlands Cancer Institute), Sven Rottenberg(University of Bern), Niels de Water(The Netherlands Cancer Institute), Ariena Kersbergen(The Netherlands Cancer Institute), Sjöfn Gunnarsdottir(The Netherlands Cancer Institute), Piet Borst(The Netherlands Cancer Institute), Jos Jonkers(The Netherlands Cancer Institute), Anders O.H. Nygren(Asana Biosciences (United States)), Eline van der Burg(The Netherlands Cancer Institute), Marina Pajic(University of Glasgow), Janneke E. Jaspers(Memorial Sloan Kettering Cancer Center), Olaf van Tellingen(Dutch Cancer Society)
Cancer Research
February 10, 2010
10.1158/0008-5472.can-09-3367
Cited by 85

Related Papers

Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
|Nature Structural & Molecular Biology|2010|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941